BIOREGULATOR / DIRECT CATALOG PRICING
Bronchogen
Bronchogen is identified in the originating literature as the tetrapeptide Ala-Asp-Glu-Leu (ADEL). This is a Russian bioregulator trade name; the name on a vial alone does not prove that sequence.
- Format
- Lyophilized research vial
- Listed formats
- 1
- Available now
- 0
- Catalog class
- Bioregulator
Choose a listed format
- 20 mgRequest current pricingRequest pricing
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
Bronchogen is identified in the originating literature as the tetrapeptide Ala-Asp-Glu-Leu (ADEL). This is a Russian bioregulator trade name; the name on a vial alone does not prove that sequence.
The bioregulator classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Bioregulator
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- Contact for current availability
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
Bronchogen is identified in the originating literature as the tetrapeptide Ala-Asp-Glu-Leu (ADEL). This is a Russian bioregulator trade name; the name on a vial alone does not prove that sequence.
- Research covered
- ADEL was tested in cultured human embryonic bronchial epithelial cells, where investigators measured gene and protein expression. Another organotypic-cell study compared Bronchogen with other short peptides in aging cell cultures.
- Important limit
- The evidence is in vitro and largely from the originating research group; it does not establish effects in humans. Independent analytical confirmation is needed to link any catalog material to ADEL.
FACTUAL FAQ
Bronchogen catalog questions
What formats are currently listed?
20 mg. Current price and stock state appear above.
What did researchers study?
ADEL was tested in cultured human embryonic bronchial epithelial cells, where investigators measured gene and protein expression. Another organotypic-cell study compared Bronchogen with other short peptides in aging cell cultures.
What is the most important evidence limit?
The evidence is in vitro and largely from the originating research group; it does not establish effects in humans. Independent analytical confirmation is needed to link any catalog material to ADEL.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →